StockData
Tarsus Pharmaceuticals, Inc. logo

Tarsus Pharmaceuticals, Inc. (TARS) stock

TARSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/304% above fair value
$78.20−0.48 (-0.61%)

Close on Nov 17, 2026Market cap $3.43BP/E –Yield 0.00%

Tarsus Pharmaceuticals price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Tarsus Pharmaceuticals's price to book ratio was 9.6× on Nov 11, 2026, against 10.1× a year earlier. Over the last 5 years it ranged from 1.7× to 10.4×, with a median of 4.8×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20269.6×−0.8
2025Dec 31, 202510.4×+1.5
2024Dec 31, 20248.9×+5.8
2023Dec 29, 20233.1×+1.2
2022Dec 30, 20221.9×−0.7
2021Dec 31, 20212.6×–

More Tarsus Pharmaceuticals figures

See a number that looks wrong?